Literature DB >> 19228490

Lipid management: considerations in acute coronary syndrome.

Venkateshwar R Polsani1, Salim S Virani, Vijay Nambi.   

Abstract

Managing dyslipidemia is an important part of the primary and secondary prevention of coronary heart disease. Low-density lipoprotein cholesterol reduction remains the primary lipid goal. Patients who have experienced an acute coronary syndrome (ACS) are at very high risk of recurrent adverse cardiovascular events. A growing body of literature supports the concept that early and intensive treatment with statins after an ACS event decreases recurrent adverse cardiovascular events. We review available evidence pertaining to lipid alterations in ACS.

Entities:  

Year:  2009        PMID: 19228490     DOI: 10.1007/s11883-009-0024-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  59 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Variations in apolipoproteins B and A1 during the course of myocardial infarction.

Authors:  P Avogaro; G B Bon; G Cazzolato; G B Quinci; A Sanson; M Sparla; G C Zagatti; G Caturelli
Journal:  Eur J Clin Invest       Date:  1978-06       Impact factor: 4.686

3.  Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study.

Authors:  C R Sirtori; L Calabresi; G Franceschini; D Baldassarre; M Amato; J Johansson; M Salvetti; C Monteduro; R Zulli; M L Muiesan; E Agabiti-Rosei
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

4.  High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

Authors:  Anders G Olsson; Gregory G Schwartz; Michael Szarek; William J Sasiela; Michael D Ezekowitz; Peter Ganz; Michael F Oliver; David Waters; Andreas Zeiher
Journal:  Eur Heart J       Date:  2005-03-11       Impact factor: 29.983

5.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.

Authors: 
Journal:  Eur Heart J       Date:  1985-03       Impact factor: 29.983

6.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-03       Impact factor: 29.690

9.  Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.

Authors:  P Koskinen; M Mänttäri; V Manninen; J K Huttunen; O P Heinonen; M H Frick
Journal:  Diabetes Care       Date:  1992-07       Impact factor: 19.112

10.  Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL.

Authors:  Nirupa R Matthan; Ann Giovanni; Ernst J Schaefer; B Greg Brown; Alice H Lichtenstein
Journal:  J Lipid Res       Date:  2003-02-01       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.